Application Note

Analysis of ccfmiRNA from Crown Bioscience’s Biobank Plasma Samples

Unlock High-Fidelity ccfmiRNA Analysis from Biobank Plasma Samples

MicroRNAs (miRNAs) in plasma are emerging as powerful biomarkers for early cancer detection, disease monitoring, and treatment response prediction. However, extracting circulating cell-free miRNA (ccfmiRNA) from plasma remains technically challenging due to low yields, variability in sample processing, and sensitivity to hemolysis.

This application note explores the performance of four cfRNA extraction kits and four blood collection tube (BCT) types using plasma samples from colorectal cancer (CRC) patients stored in Crown Bioscience’s biobank. We identify optimal workflows, protocol comparisons, RT-qPCR data, and practical recommendations to inform your own liquid biopsy research.

Download this Application Note to Learn About:

• Comparative data on ccfmiRNA extraction efficiency across multiple kits
  
  
• Impact of BCT selection on sample quality and RNA integrity
  
  
• Use of internal and external miRNA controls for method validation
  
  
• Key markers: miR-103a-3p, miR-191-5p, miR-23a-3p, miR-451a, and early CRC biomarkers miR-29a-3p and miR-92a-3p
  
  
• Best practices for assessing hemolysis risk in plasma samples

High-quality plasma biospecimens are critical for non-invasive biomarker discovery and liquid biopsy development. This study demonstrates that sample preservation, processing time, and extraction method significantly influence ccfmiRNA yield and reliability—factors that directly impact data quality and downstream insights.

Whether you're developing diagnostics, conducting translational oncology research, or building a companion diagnostic pipeline, understanding the interplay between biospecimen quality and RNA recovery is essential.

Learn how Crown Bioscience optimizes plasma biospecimen processing for ccfmiRNA analysis.

Download Now

Download Now!